Mizuho analyst Steven Valiquette lowered the firm’s price target on Phreesia (PHR) to $22 from $28 and keeps an Outperform rating on the shares. The firm trimmed targets in the healthcare technology space citing competitive risk.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
- Phreesia price target lowered to $30 from $35 at DA Davidson
- Phreesia management to meet with Citizens
- Phreesia: Transitioning to Profitable Growth Amid Oversold Valuation and Attractive Risk-Reward
- Phreesia resumed with an Outperform at RBC Capital
- Phreesia price target lowered to $25 from $29 at Citi